학술논문
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Document Type
Artikel
Author
San-Miguel, JF; Hungria, VTM; Yoon, SS; Beksac, M; Dimopoulos, MA; Elghandour, A; Jedrzejczak, WW; Gunther, A; Nakorn, TN; Siritanaratkul, N; Corradini, P; Chuncharunee, S; Lee, JJ; Schlossman, RL; Shelekhova, T; Yong, K; Tan, D; Numbenjapon, T; Cavenagh, JD; Hou, J; LeBlanc, R; Nahi, H; Qiu, LG; Salwender, H; Pulini, S; Moreau, P; Warzocha, K; White, D; Blade, J; Chen, WM; de la Rubia, J; Gimsing, P; Lonial, S; Kaufman, JL; Ocio, EM; Veskovski, L; Sohn, SK; Wang, MC; Lee, JH; Einsele, H; Sopala, M; Corrado, C; Bengoudifa, BR; Binlich, F; Richardson, PG
Source
The Lancet. Oncology. 15(11):1195-1206
Subject
Language
English
English
English
ISSN
1474-5488